Teleflex Medical

ARROW(R) Midline with Chlorag+ard(R) Technology

Arrowg+ard Blue Advance® Pressure Injectable Midline Catheter Product

4 Pages

Arrowg+ard Blue Advance® Pressure Injectable Midline Catheter Product Rx only. Product Description:  Pre-Clinical Evaluations:  The Arrowg+ard Blue Advance® catheters are processed with an external surface treatment that uses the antimicrobial chlorhexidine acetate on the catheter body and juncture hub nose, as well as an internal lumen impregnation utilizing an antimicrobial combination of chlorhexidine acetate and chlorhexidine base for the catheter body, juncture hub, extension line(s) and extension line hub(s). A maximum total amount of chlorhexidine applied to various French sizes and lengths of catheters could range up to 18.6 mg.  Arrowg+ard Blue Advance Technology has demonstrated reduction in colonization on catheter surfaces by gram-positive and gram-negative bacteria, and yeast in in vitro and in vivo studies for up to 30 days for external surface and in vitro studies for up to 30 days for fluid pathway. In addition, Arrowg+ard Blue Advance Technology has also demonstrated reduction in thrombus accumulation on catheter surfaces for up to 30 days in in vivo testing. In vitro testing has exhibited reduction in platelet adhesion on catheter surface and catheter occlusion.  Characterization of Chlorhexidine: Chlorhexidine is characterized as having a broad antimicrobial activity spectrum, including bacteriostatic and bactericidal effects on gram-positive bacteria, gram-negative bacteria and fungi. Whether chlorhexidine is bacteriostatic or bactericidal depends largely on the concentration of the agent and the susceptibility of specific organisms. Chlorhexidine (C26H38Cl2N10O4) is demonstrated to be stable at pH levels consistent with body surfaces and tissues, but also continues to show stability at lower or higher pH levels as well to ensure infused chemotherapy or other IV fluids are not impacted. Chlorhexidine also has been shown to be effective against viruses with a lipid component in their coats or with an outer envelope, but these properties have not been evaluated with this product. The antithrombogenic effect of the Arrowg+ard Blue Advance Technology on catheters appears to be a function of thrombin inhibition by chlorhexidine via intrinsic and common pathways of blood coagulation, causing delayed blood clotting response and thrombus accumulation on catheter surface.  General Warnings and Precautions Warnings: 1. Sterile, Single use: Do not reuse, reprocess or resterilize. Reuse of device creates a potential risk of serious injury and/or infection which may lead to death. Reprocessing of medical devices intended for single use only may result in degraded performance or a loss of functionality. 2. Read all package insert warnings, precautions and instructions prior to use. Failure to do so may result in severe patient injury or death.  Chlorhexidine is a cationic compound. Its positively charged molecules are strongly attracted to the negative charges present on microbial surfaces. The outer membrane of gram-negative bacteria, cell wall of gram-positive bacteria or cytoplasmic membrane of yeasts then becomes weakened from increased permeability caused by chlorhexidine being adsorbed onto the cell surface. Chlorhexidine exhibits bacteriostatic effects at low concentrations due to the release of substances characterized by low molecular weights (i.e., phosphorus and potassium ions) from the cell. This damage is enough to inhibit bacterial cell function. Bactericidal activity of chlorhexidine occurs at higher concentrations by causing precipitation of proteins and nucleic acids.  3. Remove catheter immediately if catheter-related adverse reactions occur after catheter placement. Note: Perform sensitivity testing to confirm allergy to catheter antimicrobial agents if adverse reaction occurs. 4. Clinicians must be aware of clinical conditions that may limit use of Midlines including but not limited to:  Chlorhexidine is poorly absorbed from the gastrointestinal tract. In human and animal studies, the average plasma level peaked at 0.206 μg/g in humans 30 minutes after ingesting 300 mg of chlorhexidine. Excretion occurred primarily through the feces (about 90%), and less than 1% was excreted in urine. Chlorhexidine is metabolized in the same manner as most other foreign substances. The majority will be excreted without being metabolized.  • dermatitis • cellulitis and burns at or about the insertion site  Preclinical biocompatibility studies support the conclusion that there is a negligible risk of adverse effects from the Arrowg+ard Blue Advance antimicrobial/antithrombogenic catheters.  • previous ipsilateral venous thrombosis  Indications for Use:  • radiation therapy at or about insertion site  • contractures • mastectomy • potential use for AV fistula  5. Clinicians must be aware of the potential for entrapment of guidewire by any implanted device in circulatory system. It is recommended that if patient has a circulatory system implant, catheter procedure be done under direct visualization to reduce risk of guidewire entrapment.  The Arrowg+ard Blue Advance Pressure Injectable Midline Catheter with antimicrobial and antithrombogenic technology is indicated for short-term (< 30 days) peripheral access to the venous system for intravenous therapy, blood sampling, infusion, and pressure injection of contrast media. The maximum pressure of pressure injector equipment used with the Arrow Antimicrobial and Antithrombogenic Pressure Injectable Midline Catheter may not exceed 300 psi (2068.4kPa). The maximum pressure injection flow rate for the specific lumen being used for pressure injection is printed on the extension line hub.  6. Clinician should refer to institutional policies and procedures to determine appropriate therapies for a peripheral access device.  Arrowg+ard Blue Advance Technology on the external surface of the catheter body as well as the entire fluid pathway of the catheter has been shown to be effective in reducing microbial colonization and thrombus accumulation on catheter surfaces. Antimicrobial and antithrombogenic effectiveness was evaluated using in vitro and in vivo test methods and no correlation between these testing methods and clinical outcome has currently been ascertained. It is not intended to be used for the treatment of existing infections or vein thrombosis.  7. Air embolism can occur if air is allowed to enter a vascular access device or vein. Do not leave open needles, sheaths, or uncapped, unclamped catheters in venous puncture site. Use only securely tightened Luer-Lock connectors with any vascular access device to help guard against inadvertent disconnection. 8. Clinicians should be aware that slide clamps may be inadvertently removed.  Contraindications: The Arrowg+ard Blue Advance Pressure Injectable Midline is contraindicated for patients with known hypersensitivity to chlorhexidine.  9. Use only lumen(s) labeled “Pressure Injectable” for pressure injection to reduce risk of catheter failure and/or patient complications. Refer to Arrow pressure injection label for pressure injection information.  Hypersensitivity Potential:  10. Clinicians must be aware of complications/undesirable side-effects associated with Midlines including, but not limited to:  Benefits of the use of this catheter should be weighed against any possible risk. Hypersensitivity reactions are a concern with antimicrobial catheters and can be serious and even life-threatening. 1
File Type: PDF
File Size: 669 KB
File Name: Teleflex Medical - A02041200E1 - Arrowg+ard Blue Advance® Pressure Injectable Midline Catheter Product - 2021-10 - 1.pdf

By clicking Download you are confirming this is the correct document for your purposes
and that you agree to our Terms & Conditions